sz300347
泰格医药研报 已收录392篇研报
![2021年三季报点评:主营业务加速恢复,季度业绩创新高](https://img.ulapia.com/thumbnails/stock_research/20211025/H3_AP202110251524851718_1.jpg!thumbnail_180)
![订单充裕,将持续受益于医药行业研发景气](https://img.ulapia.com/thumbnails/stock_research/20210928/H3_AP202109281519145684_1.jpg!thumbnail_180)
![公司点评报告:主营业务加速恢复,海外拓展推动转型升级](https://img.ulapia.com/thumbnails/stock_research/20210905/H3_AP202109051514339856_1.jpg!thumbnail_180)
![公司2021中报点评:国际化布局加快拓展,大临床业务持续增长](https://img.ulapia.com/thumbnails/stock_research/20210831/H3_AP202108301513346174_1.jpg!thumbnail_180)
![扣非持续亮眼,新签订单大幅增长,主业加速恢复](https://img.ulapia.com/thumbnails/stock_research/20210827/H3_AP202108271512656569_1.jpg!thumbnail_180)
![主营加速恢复,国际化布局快速拓展](https://img.ulapia.com/thumbnails/stock_research/20210827/H3_AP202108271512688403_1.jpg!thumbnail_180)
![Strong backlog growth driven by solid demand](https://img.ulapia.com/thumbnails/stock_research/20210827/H3_AP202108271512701554_1.jpg!thumbnail_180)
招银国际
Strong backlog growth driven by solid demand
页数:
4页
股票:
泰格医药(300347)
行业:
医疗行业
作者:
Jill Wu
Sam HU
Jonathan Zhao
发布日期:2021-08-27
报告全文
![2021年中报点评:21H1国际业务占比持续提升,在手订单金额增长超出预期](https://img.ulapia.com/thumbnails/stock_research/20210826/H3_AP202108261512560166_1.jpg!thumbnail_180)
光大证券
2021年中报点评:21H1国际业务占比持续提升,在手订单金额增长超出预期
页数:
3页
股票:
泰格医药(300347)
行业:
医疗行业
作者:
林小伟
发布日期:2021-08-26
报告全文
![首次覆盖报告:中国临床CRO龙头,国际业务布局加速](https://img.ulapia.com/thumbnails/stock_research/20210714/H3_AP202107141503782779_1.jpg!thumbnail_180)
![2021年一季报点评:21Q1业绩快速恢复,国际化稳步推进](https://img.ulapia.com/thumbnails/stock_research/20210430/H3_AP202104301488767223_1.jpg!thumbnail_180)